Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Department of Cell Engineering, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Trends Biotechnol. 2018 Apr;36(4):358-371. doi: 10.1016/j.tibtech.2017.12.005. Epub 2018 Jan 20.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in more accurate predictions of drug responses in patients. Tumor organoid models have several advantages over pre-existing models, including conserving the molecular and cellular composition of the original tumor. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly preclinical drug screening and predicting patient responses to selected treatment regimens. Here, we highlight the advantages, challenges, and translational potential of tumor organoids in personalized cancer therapy and focus on gene-drug associations, drug response prediction, and treatment selection. Finally, we discuss how microfluidic technology can contribute to immunotherapy drug screening in tumor organoids.
个体化癌症治疗为每位患者提供特定的治疗方案。使用与原始肿瘤具有相似特征的个体化肿瘤模型可能会导致更准确地预测患者对药物的反应。肿瘤类器官模型相对于现有模型具有几个优势,包括保留原始肿瘤的分子和细胞组成。这些优势突出了肿瘤类器官在个体化癌症治疗中的巨大潜力,特别是在临床前药物筛选和预测患者对选定治疗方案的反应方面。在这里,我们强调了肿瘤类器官在个体化癌症治疗中的优势、挑战和转化潜力,并重点讨论了基因-药物关联、药物反应预测和治疗选择。最后,我们讨论了微流控技术如何有助于肿瘤类器官中的免疫疗法药物筛选。